JP2021520393A5 - - Google Patents
Info
- Publication number
- JP2021520393A5 JP2021520393A5 JP2020554864A JP2020554864A JP2021520393A5 JP 2021520393 A5 JP2021520393 A5 JP 2021520393A5 JP 2020554864 A JP2020554864 A JP 2020554864A JP 2020554864 A JP2020554864 A JP 2020554864A JP 2021520393 A5 JP2021520393 A5 JP 2021520393A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- amino acid
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024018521A JP7829605B2 (ja) | 2018-04-02 | 2024-02-09 | コネキシン４３抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862651668P | 2018-04-02 | 2018-04-02 | |
| US62/651,668 | 2018-04-02 | ||
| PCT/US2019/025363 WO2019195273A1 (en) | 2018-04-02 | 2019-04-02 | Connexin 43 antibodies and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024018521A Division JP7829605B2 (ja) | 2018-04-02 | 2024-02-09 | コネキシン４３抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520393A JP2021520393A (ja) | 2021-08-19 |
| JP2021520393A5 true JP2021520393A5 (enExample) | 2022-04-11 |
| JP7437317B2 JP7437317B2 (ja) | 2024-02-22 |
Family
ID=68101187
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554864A Active JP7437317B2 (ja) | 2018-04-02 | 2019-04-02 | コネキシン４３抗体およびその使用 |
| JP2024018521A Active JP7829605B2 (ja) | 2018-04-02 | 2024-02-09 | コネキシン４３抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024018521A Active JP7829605B2 (ja) | 2018-04-02 | 2024-02-09 | コネキシン４３抗体およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12227561B2 (enExample) |
| JP (2) | JP7437317B2 (enExample) |
| CN (2) | CN116854816A (enExample) |
| AU (1) | AU2019249427B2 (enExample) |
| CA (1) | CA3095897A1 (enExample) |
| WO (1) | WO2019195273A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12227561B2 (en) | 2018-04-02 | 2025-02-18 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| IL285369B2 (en) * | 2019-02-04 | 2025-10-01 | Alamab Therapeutics Inc | Connexin 43 antibodies and their use |
| US20220162298A1 (en) * | 2019-02-28 | 2022-05-26 | Board Of Regents, The University Of Texas System | Compositions for treating osteosarcoma and methods of use |
| AU2020358101A1 (en) * | 2019-10-02 | 2022-04-28 | Alamab Therapeutics, Inc. | Anto-connexin antibody formulations |
| CN113307871B (zh) * | 2020-02-27 | 2023-05-02 | 福州拓新天成生物科技有限公司 | 新型抗cd19抗体和cd19-car-t细胞的制备及其应用 |
| JP2023537316A (ja) * | 2020-07-31 | 2023-08-31 | アラマブ セラピューティクス， インコーポレイテッド | 抗コネキシン抗体製剤 |
| WO2024243439A2 (en) * | 2023-05-24 | 2024-11-28 | Alamab Therapeutics, Inc. | Method of treating bone cancers |
| US12571255B2 (en) | 2023-06-02 | 2026-03-10 | Universal Electronics Inc. | Systems and method for controlling window treatments |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| EP3960855A1 (en) | 2001-12-28 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing proteins |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| KR101225299B1 (ko) | 2003-12-10 | 2013-01-24 | 메다렉스, 인코포레이티드 | 인터페론 알파 항체 및 그의 용도 |
| DK1959981T3 (da) | 2005-02-03 | 2020-01-27 | Coda Therapeutics Ltd | Anti-connexin 43 forbindelser til behandling af kroniske sår |
| MX2010012324A (es) * | 2008-05-15 | 2011-01-14 | Biogen Idec Inc | Anticuerpos anti-fn14 y usos de los mismos. |
| US20110223204A1 (en) | 2008-06-04 | 2011-09-15 | Bradford J Duft | Treatment of pain with gap junction modulation compounds |
| CN103429732B (zh) | 2010-12-27 | 2015-09-16 | Lsip基金运营联合公司 | iPS细胞及其制造方法 |
| CA2921652A1 (en) * | 2013-08-21 | 2015-02-26 | Manuel A. Riquelme | Compositions and methods for targeting connexin hemichannels |
| US9493552B2 (en) * | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
| US10465188B2 (en) | 2014-08-22 | 2019-11-05 | Auckland Uniservices Limited | Channel modulators |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| EP3419998A4 (en) * | 2016-02-26 | 2019-09-25 | The Board of Regents of The University of Texas System | CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF |
| US12227561B2 (en) | 2018-04-02 | 2025-02-18 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| IL285369B2 (en) | 2019-02-04 | 2025-10-01 | Alamab Therapeutics Inc | Connexin 43 antibodies and their use |
| JP2023537316A (ja) * | 2020-07-31 | 2023-08-31 | アラマブ セラピューティクス， インコーポレイテッド | 抗コネキシン抗体製剤 |
-
2019
- 2019-04-02 US US17/045,001 patent/US12227561B2/en active Active
- 2019-04-02 WO PCT/US2019/025363 patent/WO2019195273A1/en not_active Ceased
- 2019-04-02 CA CA3095897A patent/CA3095897A1/en active Pending
- 2019-04-02 AU AU2019249427A patent/AU2019249427B2/en active Active
- 2019-04-02 CN CN202310053523.1A patent/CN116854816A/zh active Pending
- 2019-04-02 JP JP2020554864A patent/JP7437317B2/ja active Active
- 2019-04-02 CN CN201980024875.6A patent/CN112368299A/zh active Pending
-
2024
- 2024-02-09 JP JP2024018521A patent/JP7829605B2/ja active Active
-
2025
- 2025-01-13 US US19/019,170 patent/US20250289876A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520393A5 (enExample) | ||
| JP2020537644A5 (enExample) | ||
| RU2376316C2 (ru) | Человеческие антитела против человеческого 4-1вв (cd137) | |
| JP2023510350A5 (enExample) | ||
| JP2020062036A5 (enExample) | ||
| JP2020519643A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2019527194A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2017532952A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| JP2008542278A5 (enExample) | ||
| JP2014076062A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| JP2015509948A5 (enExample) | ||
| JP2013537418A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| JP2015503909A5 (enExample) |